Functional Characterization Of Risk Factor Involved In Mptp-Induced Parkinsonism In Mice / (Record no. 608901)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01788nam a22001577a 4500 |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 610 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Jatala, Faria Hasan |
| 245 ## - TITLE STATEMENT | |
| Title | Functional Characterization Of Risk Factor Involved In Mptp-Induced Parkinsonism In Mice / |
| Statement of responsibility, etc. | Faria Hasan Jatala |
| 264 ## - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Islamabad : |
| Name of producer, publisher, distributor, manufacturer | SMME- NUST; |
| Date of production, publication, distribution, manufacture, or copyright notice | 2022. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 72p. |
| Other physical details | Soft Copy |
| Dimensions | 30cm |
| 500 ## - GENERAL NOTE | |
| General note | The second-most prevalent neurological disease in the world, Parkinson's disease (PD) affects<br/>roughly 4 million people. The death and loss of dopaminergic neurons in the substantia nigra<br/>compacta (SNpc) is the primary pathogenic characteristic of PD. Motor abnormalities include limb<br/>stiffness, tremor, and bradykinesia are the major features of PD. Although levodopa (L-DOPA) is<br/>the gold standard medication, but it has clear negative effects when taken over an extended period.<br/>Therefore, it is vital that novel medicines and ideal therapeutic agents be discovered. Parkinson's<br/>disease remains an unsolved clinical problem, as currently authorized PD therapies offer relatively<br/>modest therapeutic benefits. New therapeutic approaches that not only alleviate symptoms in the<br/>short term but also stop the disease from getting worse are desperately needed. For this purpose,<br/>mice model is utilized for PD induction by MPTP neurotoxin for functional characterization of<br/>proteomic factor GFAP as a risk factor in an effort to enhance the efficacy of the treatment of PD.<br/>In future, by targeting pathway of GFAP level in substantia nigra with some targeted drug will<br/>eventually lead to innovative therapeutic approach for PD patients. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | MS Biomedical Sciences (BMS) |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Supervisor : Dr. Saima Zafar |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://10.250.8.41:8080/xmlui/handle/123456789/31048">http://10.250.8.41:8080/xmlui/handle/123456789/31048</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Thesis |
| Withdrawn status | Permanent Location | Current Location | Shelving location | Date acquired | Full call number | Barcode | Koha item type |
|---|---|---|---|---|---|---|---|
| School of Mechanical & Manufacturing Engineering (SMME) | School of Mechanical & Manufacturing Engineering (SMME) | E-Books | 04/22/2024 | 610 | SMME-TH-776 | Thesis |